Compare Moderna, Inc. (MRNA) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Snowflake Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Snowflake Inc trades at $368.89 (market cap $121.15B). The key difference: Snowflake Inc is the larger of the two by market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 3,986,549). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Snowflake Inc for 54 Days on average.
| MRNA | SNOW | |
|---|---|---|
Market Cap | $78.65B | $121.15B |
Volume | 37,373,437 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $225.00 | $368.89 |
52-Week Low | $22.36 | $121.11 |
Typical Hold Time | 59 Days | 54 Days |
Enterprise Value | $74.80B | $121.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $3.63 billion in 2025 but remains unprofitable with a net income margin of -20.07%. Recent positive developments include strategic partnerships with UiPath and a $3.75 billion convertible note offering to fund growth initiatives.
Snowflake presents a growth investment opportunity with strong analyst support (81% buy ratings) and a $418 price target, but faces execution risks from persistent losses and high valuation multiples. The stock's upside depends on continued revenue expansion and path to profitability amid competitive cloud data market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
